0


(Reuters) – Agenus Inc said a mid-stage trial of its experimental genital herpes vaccine reduced the rate at which patients’ were shedding the virus.

The 15 percent reduction in viral shedding in patients receiving the vaccine compared to those on a placebo, who showed no reduction.

The mid-stage trial had 80 patients with a history of 1-9 herpes recurrences within the prior 12 months. Of them, 70 received the vaccine, HerpV, and 10 received placebo.

(Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)

//

Advertisement
You have just read the article News for today's that category by title Agenus genital herpes vaccine succeeds in mid-stage trial [ BeritaTerkini ]. You can bookmark this page with a URL http://news-these-days.blogspot.com/2013/11/agenus-genital-herpes-vaccine-succeeds.html. Thank you!
Thursday, November 7, 2013

Post a Comment

 
Top